Aventis, the French pharmaceutical company, signed its long-awaited euro1.5 billion ($1.31 billion) Euro-MTN programme on September 20 via UBS Warburg. The dealers off the facility are the arranger, BNP Paribas, Deutsche Bank, Morgan Stanley Dean Witter, and Salomon Smith Barney. The programme, rated A3 by Moody's, marks the ninth French corporate issuer to come to the market this year. It has been a busy period for French corporates, with French signings making up 41% of all new corporate programmes this year. Aventis, formed when France's Rhone-Poulenc and Germany's Hoechst merged, has become the world's number one drug company. As a pure life-sciences company, Aventis makes animal health products, herbicides, pesticides, cancer drugs, and other pharmaceuticals. Rhodia, a spin-off from the same merger that produced Aventis, also signed a euro1.5 billion Euro-MTN shelf this year. The facility has $750.53 million outstanding off two trades.
October 06, 2000